신경보호제 : 치료 용도와 세계 시장

The global market for neuroprotective agents is expected to grow from $43.9 billion in 2025 and is projected to reach $60.9 billion by the end of 2030, at a compound annual growth rate (CAGR) of 6.7% during the forecast period of 2025 to 2030.

The North American market for neuroprotective agents is expected to grow from $18.2 billion in 2025 and is projected to reach $25.4 billion by the end of 2030, at a CAGR of 6.9% during the forecast period of 2025 to 2030.

The European market for neuroprotective agents is expected to grow from $12.4 billion in 2025 and is projected to reach $16.8 billion by the end of 2030, at a CAGR of 6.2% during the forecast period of 2025 to 2030.

Report Scope

This report presents both qualitative and quantitative data on the current market dynamics and trends in the global neuroprotective agents market. It also assesses pipeline drugs that are under development. The study further includes analyses of various products offered by companies, new strategies implemented by major manufacturers and emerging technologies. It discusses the market prospects for five regions-North America, Europe, Asia-Pacific, South America, and the Middle East and Africa (MEA) and includes profiles of leading companies and their strategies.

This report focuses on different indications, such as neurodegenerative disorders, cerebrovascular disease, ophthalmic diseases and central nervous system (CNS) injuries. It segments neurodegenerative disorders into multiple sclerosis, Alzheimer's disease, epilepsy, Parkinson's disease, amyotrophic lateral sclerosis (ALS), spinal muscular atrophy, and Huntington's disease. Ophthalmic diseases are segmented into age-related macular degeneration, glaucoma and other ophthalmic diseases. Based on drug class, the market is divided into immune response modifiers, blood thinning agents, anti-angiogenic agents, antioxidants, ocular hypotensives, anti-dementia agents, anticonvulsants, thrombolytics, anti-Parkinson's agents, antisense agents, anti-amyloid agents and other neuroprotective agents.

On the basis of therapy type, the overall market is segmented into small molecule drugs, monoclonal antibodies, cell therapies, gene therapies and other biotechnology products. The report also covers market projections throughout 2030 and company profiles. By geography, it is segmented into North America, Europe, Asia-Pacific, the MEA, and South America. North America includes the U.S., Canada, and Mexico; Europe includes Germany, the U.K., France, Italy, Spain, and the Rest of Europe; and Asia-Pacific includes China, India, Japan, and the Rest of Asia-Pacific. The study provides market estimates for 2024, with forecasts for 2025 through 2030.

Report Includes

• 54 data tables and 56 additional tables
• An overview of the global market for neuroprotective agents and their therapeutic applications
• In-depth analysis of global market trends, featuring historical revenue data for 2022-2025, as well as forecasts for 2030. This analysis includes projections of compound annual growth rates (CAGRs) through 2030
• Evaluation of the current market size and revenue growth prospects specific to the neuroprotective agents, accompanied by a market share analysis by therapy type, indication, drug class, and region
• Analysis of current and future demand in the global neuroprotective agents market, along with a detailed analysis of the competitive environment, market regulations and reimbursement practices
• Analysis of drivers, challenges and opportunities affecting market growth
• Coverage of evolving technologies, the current and future market potential, R&D activities, growth strategies, new product pipeline, regulatory framework and reimbursement scenarios, and ESG trends of the market
• Market share analysis of the key market participants in the neuroprotective agents market, along with their research priorities, product portfolios, global rankings and competitive landscape
• Profiles of major companies within the industry, including Novartis AG, Biogen, Bayer AG, Sanofi, and Teva Pharmaceutical Industries Ltd.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary
• Market Dynamics and Growth Factors
• Emerging Technologies
• Segmental Analysis
• Regional Analysis
• Conclusion

Chapter 2 Market Overview

• Overview
• PESTLE Analysis
• Political Factors
• Economic Factors
• Social Factors
• Technological Factors
• Legal Factors
• Environmental Factors
• Porter's Five Forces Analysis
• Potential for New Entrants (Moderate to Low)
• Bargaining Power of Suppliers (Moderate)
• Bargaining Power of Buyers (Moderate)
• Threat of Substitute Products (Moderate)
• Industry Level of Competitiveness (High)

Chapter 3 Market Dynamics

• Overview
• Market Drivers
• Surge in Neurological Disorders Across the Globe
• Rising Prevalence of Neurological Conditions Among the Elderly
• Rising Awareness for Neuroprotective Agents
• Market Restraints
• High Cost of Drug Development
• Failure of Clinical Trials in the Neuroprotective Product Line
• Market Opportunity
• Rising Healthcare Investments
• Strategic Implications for a Pharmaceutical or Biotech Company

Chapter 4 Regulatory Landscape

• Overview
• Regulatory Scenario in the U.S.
• Regulatory Scenario in Europe
• Regulatory Scenario in Japan
• Other Countries

Chapter 5 Emerging Technologies and Developments

• Emerging Technologies
• Precision Medicine in Neurological Disorders
• Gene Therapy for Neurological Disorders
• Neurodegeneration and Stem Cell Therapy
• Nanotechnology in Neuroscience
• Conclusion
• Pipeline Analysis
• Key Takeaways
• Patent Analysis
• Key Takeaways

Chapter 6 Market Segmentation Analysis

• Segmentation Breakdown
• Market Breakdown by Indication
• Takeaways
• Cerebrovascular Disease
• Neurodegenerative Disorders
• Ophthalmic Diseases
• CNS Injury
• Market Breakdown by Therapy Type
• Takeaways
• Small Molecule Drugs
• Monoclonal Antibodies
• Cell Therapies
• Gene Therapies
• Other Biotechnology Products
• Market Breakdown by Drug Class
• Takeaways
• Immune Response Modifiers
• Blood Thinning Agents
• Anti-angiogenic Agents
• Antioxidants
• Ocular Hypotensive
• Anti-Dementia Agents
• Anticonvulsants
• Thrombolytics
• Anti-Parkinson's Agents
• Antisense Agents
• Anti-Amyloid Agents
• Other Neuroprotective Agents
• Geographic Region
• Market Breakdown by Region
• Takeaways
• North America
• Europe
• Asia-Pacific
• South America
• Middle East and Africa (MEA)

Chapter 7 Competitive Intelligence

• Key Takeaways
• Competitive Analysis
• Strategic Initiatives

Chapter 8 Sustainability in Neuroprotective Agents Industry: ESG Perspective

• Overview
• Key Strategies for Sustainable Drug Manufacturing
• Green Chemistry Integration
• Energy and Resource Efficiency
• Sustainable Raw Material Sourcing
• Waste Minimization and Circular Economy Practices
• Digitalization and Smart Manufacturing
• Regulatory Compliance and Green Certification
• Collaborative Innovation and Knowledge Sharing
• Sustainable Product Lifecycle Management
• ESG Risk Ratings
• Concluding Remarks from BCC Research

Chapter 9 Appendix

• Research Methodology
• Sources
• Abbreviations
• Company Profiles
• ABBVIE INC.
• ASTRAZENECA
• BAYER AG
• BIOGEN
• BOEHRINGER INGELHEIM INTERNATIONAL GMBH
• BRISTOL-MYERS SQUIBB CO.
• DAIICHI SANKYO CO. LTD.
• F. HOFFMANN-LA ROCHE LTD.
• GSK PLC.
• LILLY USA LLC.
• MERCK & CO. INC.
• NOVARTIS AG
• SANOFI
• TEVA PHARMACEUTICAL INDUSTRIES LTD.
• UCB S.A.
• Emerging Start-ups/Market Disruptors